z-logo
open-access-imgOpen Access
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
Author(s) -
Rajendra H. Mehta,
Jeffrey D. Leimberger,
Sean van Diepen,
James M. Meza,
Alice Wang,
Rachael Jankowich,
Robert W. Harrison,
Douglas W.P. Hay,
Stephen E. Fremes,
Andra I. Duncan,
Edward G. Soltesz,
John M. Luber,
Soon Park,
Michael Argenziano,
Edward Murphy,
Randy J. Marcel,
Dimitri Kalavrouziotis,
Dave Nagpal,
John Bozinovski,
Wolfgang Toller,
Matthias Heringlake,
Shaun G. Goodman,
Jerrold H. Levy,
Robert A. Harrington,
Kevin J. Anstrom,
John H. Alexander
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1616218
Subject(s) - medicine , levosimendan , ejection fraction , placebo , cardiac surgery , clinical endpoint , myocardial infarction , perioperative , anesthesia , cardiopulmonary bypass , cardiology , population , inotrope , randomized controlled trial , surgery , heart failure , alternative medicine , environmental health , pathology
Levosimendan is an inotropic agent that has been shown in small studies to prevent or treat the low cardiac output syndrome after cardiac surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom